The Department of Radiology at the Penn State Health Milton S. Hershey Medical Center is seeking a full-time subspecialty trained candidate in the Division of Nuclear Medicine.   The successful candidate will need to have subspecialty fellowship training in nuclear medicine and have or be eligible for either a CAQ in nuclear medicine from the ABR or ABNM certification.  The position will require interpretation of diagnostic adult and pediatric nuclear medicine examinations as well as radioactive therapeutic procedures.  Special consideration will be given to candidates with an academic interest in either oncologic imaging and theranostics, or neuromolecular imaging and application to neurocognitive diseases. There is opportunity for interdisciplinary clinical research through collaboration with our basic science investigators in the Penn State Center for NMR Research and MRI Core Research facility.  This Center has 4 research faculty with unique expertise in application of fMRI and quantitative imaging biomarkers in the study of neurocognitive diseases and brain trauma. The Department recently established an imaging core lab to support the development and application of imaging biomarkers for clinical research and the Division of Radiology Innovation and Value Enhancement (DRIVE) for support of informatics and advanced data analytics for research and process improvement.

The Department has a strong commitment to serve the clinical, education, and research mission of the University and a collegial and collaborative relationship with the clinical services.  The Division of Nuclear medicine has 3 fellowship trained faculty and sponsors an ACGME fellowship in nuclear medicine and molecular imaging.  A passion for teaching is essential as the education of our medical students, residents, fellow, and staff is a core value of our academic mission. This position offers flexible arrangements with the opportunity for one to two remote workdays per week, and no overnight or evening call, supporting a healthy work–life balance.

The Department has state of the art diagnostic imaging equipment including:

• PET/CT scanner (Biograph mCT) – features include diagnostic 16 slice CT scanner combined with a dual-headed SPECT gamma camera; ability to perform molecular imaging with reproducible quantification; superb volumetric resolution; minimum dose and maximum speed molecular imaging
• Two modern Symbia Intevo hybrid SPECT/CT systems – features include a diagnostic 16 slice CT scanner combined with a dual-headed SPECT gamma camera; XSPECT and XQUANT; provides precise anatomic localization to guide diagnostic and therapeutic interventions
• Three dual-head SPECT gamma cameras
• One dedicated cardiac SPECT gamma camera
• Atom 950 thyroid uptake system
• Two Hologic Horizon A bone densitometers
• One Hologic Discovery A bone densitometer

UNIQUE FACILITIES

Ultramodern USP 797 compliant nuclear pharmacy permitting on-site radiopharmaceutical compounding

REGIONALLY UNIQUE SERVICES

THERAPEUTIC SERVICES

• PLUVICTO™ (lutetium Lu177 vipivotide tetraextan) – targeted radiotherapy for men with PSMA positive advanced metastatic prostate cancer. Penn State Hershey was one of three initial hospitals in Pennsylvania to offer this novel treatment beginning in July 2022
• LUTATHERA™ (lutetium Lu177 dotatate) – a targeted radiotherapy for patients with somatostatin receptor positive low-to-intermediate grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

DIAGNOSTIC SERVICES

• CERIANNA™ (fluoroestradiol F18) – targeted PET/CT imaging study for Estrogen receptor positive breast carcinoma and lobular breast carcinoma. Introduced in November 2021.
• PYLARIFY™ (piflufolastat F18) and LOCAMETZ™ (gallium Ga68 gozetotide) – targeted PET/CT imaging for localization of PSMA receptor positive lesions in prostate cancer. Introduced in November 2021 and March 2022, respectively.
• NETSPOT (gallium Ga68 dotatate) and DETECTNET™ (copper Cu64 dotatate) PET imaging for localization of somatostatin receptor positive neuroendocrine tumors
• AMYVID® (fluorbetapir F18) PET imaging for estimating beta amyloid neuritic plaque density for patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes of cognitive decline.
• PET myocardial Perfusion Imaging – initiated in February 2021
• PET imaging for cardiac sarcoidosis
• Tc-99m pyrophosphate imaging for the detection of transthyretin cardiac (ATTR) amyloidosis
• Xofigo™ (radium Ra 223 dichloride) for treatment of castrate-resistant prostate cancer that is metastatic to bone
• Y-90 selective internal radiation therapy (performed in conjunction with the interventional radiology service) for treatment of hepatic cancers and liver metastasis
• DaTscan™ (ioflupane I123) imaging for evaluation of patients with suspected parkinsonian disorders

Hershey, PA is a town of 15,000 residents and part of the greater metropolitan Harrisburg area within 2 hours of Washington D.C., Baltimore and Philadelphia.  Excellent schools, a safe and friendly environment, excellent outdoor sports opportunities and a commute time of 5 – 10 minutes make for a family friendly active life in Central PA.

For additional information, please contact:

Nicole Brandt, Physician Recruiter; Email:  nbrandt@pennstatehealth.psu.edu

Penn State Health is an Equal Opportunity Employer and does not discriminate on the basis of any protected class including disability or veteran status.  Penn State Health’s policies and objectives are in direct compliance with all federal and state constitutional provisions, laws, regulations, guidelines, and executive orders that prohibit or outlaw discrimination.

About Penn State Health

Connections working at Penn State Health